Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Buy” by Analysts

Kura Oncology, Inc. (NASDAQ:KURA) has received an average rating of “Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued a report on the stock in the last year is $30.50.

A number of research firms have recently weighed in on KURA. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th. Stifel Nicolaus reduced their price objective on Kura Oncology from $28.00 to $26.00 and set a “buy” rating for the company in a report on Friday, August 9th. StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Friday, August 9th. Finally, Wedbush reissued an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Friday, August 9th.

Institutional Trading of Kura Oncology

A number of institutional investors have recently added to or reduced their stakes in KURA. 1492 Capital Management LLC increased its position in shares of Kura Oncology by 1.0% during the fourth quarter. 1492 Capital Management LLC now owns 101,500 shares of the company’s stock valued at $1,460,000 after buying an additional 1,034 shares during the period. Signaturefd LLC lifted its stake in Kura Oncology by 40.4% in the 4th quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock worth $72,000 after purchasing an additional 1,449 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Kura Oncology by 9.7% in the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock valued at $384,000 after purchasing an additional 1,588 shares during the period. Aaron Wealth Advisors LLC boosted its holdings in Kura Oncology by 2.4% in the 2nd quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock valued at $1,444,000 after purchasing an additional 1,673 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Kura Oncology by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after purchasing an additional 1,976 shares during the period.

Kura Oncology Stock Up 2.7 %

KURA stock opened at $21.06 on Tuesday. The stock has a market cap of $1.60 billion, a P/E ratio of -9.71 and a beta of 0.88. The company has a current ratio of 16.67, a quick ratio of 16.67 and a debt-to-equity ratio of 0.02. The stock’s fifty day simple moving average is $20.40 and its two-hundred day simple moving average is $20.67. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. During the same quarter in the previous year, the company earned ($0.53) earnings per share. The company’s revenue was up .0% on a year-over-year basis. Analysts expect that Kura Oncology will post -2.56 EPS for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.